Semax: from 1991 lab bench to today

Semax is a synthetic heptapeptide that exists in two worlds at once. In Russia it is a licensed prescription medicine, on the country's List of Vital & Essential Drugs since December 2011, dispensed as a nasal spray in stroke-rehabilitation wards and cognitive-disorder clinics. Everywhere else in the world it is an unapproved compound sold through grey-market channels. Understanding how it got there requires tracing roughly three decades of Soviet-era pharmacology, Russian regulatory decisions, and a publication record that is both substantial and, by Western standards, methodologically uneven. This is that story, drawn from the primary literature^[1].

1991: the heptapeptide takes shape in Moscow

The earliest published work comes from Potaman and colleagues at the Institute of Molecular Genetics of the Russian Academy of Sciences. Their 1991 paper in Biochemical and Biophysical Research Communications studied enzymatic degradation of ACTH(4-10) and its synthetic analog Semax in rat blood^[2]. The key design insight was structural: by appending a Pro-Gly-Pro tail to the ACTH(4-7) tetrapeptide, the scientists produced a compound the authors confirmed was 'more stable than ACTH(4-10) against the action of other enzymes.' Stability in blood was a prerequisite for the compound to reach the brain via the intranasal route. The design also relied on earlier Soviet-era work showing ACTH fragments carry cognitive effects without the cortisol-stimulating action of full-length ACTH, allowing researchers to develop neuroprotective properties without an unwanted hormonal cascade.

1997: the first clinical signal in ischemic stroke

In 1997 Gusev and colleagues at the Pirogov Russian National Research Medical University published clinical and electrophysiological findings in patients with acute hemispheric ischemic stroke^[3]. The study established the research group and the indication, stroke recovery, that would anchor Russian Semax work for two decades. The standard Russian dosing regimen, two 10-day intranasal courses at 6,000 micrograms per day separated by a 20-day interval, traces to this period.

2005 to 2006: the mechanism papers

Two papers published in 2005 and 2006 gave the research field a mechanistic framework for Semax's effects on the brain. Eremin and colleagues (2005) reported that Semax raises striatal serotonin metabolite levels by roughly 25% within two hours in rats, and that it 'dramatically enhanced' dopaminergic effects when given before D-amphetamine^[4]. The finding established that a compound designed as a cognitive enhancer was also modulating the monoaminergic systems that regulate mood, motivation, and motor function.

The 2006 paper by Dolotov and colleagues in the Journal of Neurochemistry filled in another piece. Intranasal Semax at 50 and 250 micrograms per kilogram produced a rapid rise in brain-derived neurotrophic factor protein in the rat basal forebrain within three hours of administration, with regional specificity (the cerebellum did not respond)^[5]. BDNF is a growth and survival protein for neurons, central to memory formation and neuroprotection. Elevating BDNF in the basal forebrain, the brain region most directly involved in attention and memory, provided a plausible cellular explanation for the cognitive effects Russian clinicians were reporting in stroke patients.

2011: Russia grants formal prescription status

On 7 December 2011 the Russian Federation added Semax to the List of Vital & Essential Drugs, formalising its status as a prescription medicine with indications covering ischemic stroke recovery, transient ischemic attack, memory and cognitive disorders, and optic-nerve disease. By 2011 Semax had been in clinical use in Russia for at least a decade; the listing codified existing practice rather than marking a new approval. The EMA had never evaluated the compound^[1], the FDA had not approved it, and no sponsor had filed a dossier to either agency. Russian regulatory status conferred no recognition from Western regulators.

2018: the follow-up clinical study with BDNF biomarker

Gusev and colleagues returned to the literature in 2018 with the most cited Russian clinical study of Semax: 110 patients at different stages of ischemic stroke, divided into early and late rehabilitation groups with and without Semax treatment^[3]. The study measured plasma BDNF concentrations, motor performance on the British Medical Research Council scale, and activities of daily living on the Barthel index. Semax administration raised plasma BDNF regardless of rehabilitation timing. Motor and Barthel scores improved most with the combination of early rehabilitation and Semax. The study's conclusion, 'early rehabilitation and administration of Semax increase BDNF plasma level, speed functional recovery, and improve motor performance,' became the most-quoted summary of the Russian clinical evidence base.

The methodological caveats matter. The PubMed abstract does not describe the 2018 study as fully randomised and double-blind. It was single-centre, and 110 patients is far smaller than the multi-thousand-participant datasets Western regulators expect for a major neurological indication. None of this invalidates the finding, but it explains why it has not moved Semax toward a Western approval.

2025 and beyond: new mechanisms, unresolved approvals

The most recent significant mechanism paper appeared in the British Journal of Pharmacology in 2025. Liu and colleagues at a Chinese research institution reported that Semax improved functional recovery and reduced neuroinflammation in a female mouse spinal-cord-injury model, identifying the mu-opioid receptor gene Oprm1 as a therapeutic target^[6]. The finding extended the Semax mechanism picture beyond the BDNF and monoaminergic pathways characterised in the 2005 and 2006 papers, and it came from a research group outside Russia, a first for major Semax mechanism work.

Also in 2025, a team at the Institute of Molecular Genetics published work showing Semax and a derivative peptide reduced amyloid plaque density in the cortex and hippocampus of APPswe/PS1dE9 Alzheimer's transgenic mice and improved cognitive performance across three behavioural tests^[7]. The Alzheimer's work is preclinical, but it points to where Russian researchers believe the next clinical investigation may lead.

As of mid-2026, Semax remains a prescription medicine in Russia and an unapproved compound everywhere else. The Semax peptide page carries the full regulatory picture across Denmark, Sweden, Norway, Germany, the Netherlands, the UK, and the US: no marketing authorisation and no approved supply chain in any of them.

What we do not know

More than 200 papers on Semax are indexed in PubMed, but the gaps that matter for Western regulators remain open. There is no completed phase-2 or phase-3 randomised controlled trial run to FDA or EMA standards. There is no characterised dose-response curve for cognitive endpoints in healthy adults. The BDNF-elevation documented in rats has not been confirmed in humans at clinically used doses. A 2026 review in Frontiers in Aging classified Semax among peptides that 'showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation'^[8]. That is an accurate summary of where the evidence stands today. For regulatory detail and grey-market quality risks, see the Semax regulation pages.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Semax is not approved for human use by the FDA, EMA, or MHRA. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.